Emerging Biomarkers in Hypertension

• Conditions: Hypertension
• Interventions: Drug: Anti-hypertensive drugs

• Registration Number: NCT02064218
• Lead Sponsor: University of Pavia

Brief Summary

First of all to evaluate the relationship between non-conventional biomarkers and essential hypertension; then to evaluate the effects of various anti-hypertensive drugs on blood pressure control and non-conventional biomarkers in naive hypertensive patients

Detailed Description

Not available

Study Timeline

• Status Verified: 2007-11
• Study Start: 2007-11
• Primary Completion: 2014-01
• Study First Submitted: 2014-02-11
• Study First Submitted QC: 2014-02-13
• Last Update Submitted: 2014-02-13
• Study First Posted: 2014-02-17
• Last Update Posted: 2014-02-17

Recruitment & Eligibility

• Status: UNKNOWN
• Sex: All
• Target Recruitment: Not specified

Inclusion Criteria

• essential hypertension
• naive to treatment
• < 65 years

Exclusion Criteria

• secondary hypertension
• previous cardiovascular events

Study & Design

• Study Type: OBSERVATIONAL
• Study Design: Not specified

Arm && Interventions

Group	Intervention	Description
Hypertensive patients	Anti-hypertensive drugs	Hypertensive patients naive to hypertensive treatment

Primary Outcome Measures

Name	Time	Method
Blood pressure reduction	5 years	* Systolic Blood Pressure (SBP); * Diastolic Blood Pressure (DBP)

Secondary Outcome Measures

Name	Time	Method
Cardiovascular and metabolic biomarkers	5 years	* Lipoprotein (a) (Lp(a)); * sRAGE (soluble Receptor for Advanced Glycation End-products); * sCD40L (soluble ligand of CD40); * MPO (myeloperoxidase)

Trial Locations

Locations (1)

IRCCS Policlinico S.Matteo Foundation; 🇮🇹 Pavia, Italy